肿瘤学中分子靶向治疗的皮肤并发症
Cutaneous complications of molecular targeted therapy used in oncology.
作者信息
Lupu I, Voiculescu N, Bacalbasa N, Cojocaru I, Vrancian V, Giurcaneanu C
机构信息
Department of Dermatology, "Elias" University Hospital, Bucharest, Romania.
Department of Dermatology, "Elias" University Hospital, Bucharest, Romania; "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
出版信息
J Med Life. 2016 Jan-Mar;9(1):19-25.
Abstract
UNLABELLED
The new molecular targeted therapy has been developed over the past decades by using the molecular targeted molecular changes discovered in specific types of cancer. Unfortunately, most of these agents (epidermal growth factor receptors, multi-targeted small molecule tyrosine kinase inhibitors, monoclonal antibodies) have severe cutaneous adverse reactions, that not only interfere with the patient's quality of life, but also are dose-limiting and may require treatment interruptions. These cutaneous complications and their management must be very well known by any oncologist and dermatologist who treat oncologic patients.
ABBREVIATIONS
EGFR = epidermal growth factor receptors, EGFRI = epidermal growth factor receptors inhibitors.
摘要
未标注
在过去几十年中，通过利用在特定类型癌症中发现的分子靶向分子变化，开发出了新的分子靶向疗法。不幸的是，这些药物中的大多数（表皮生长因子受体、多靶点小分子酪氨酸激酶抑制剂、单克隆抗体）都有严重的皮肤不良反应，这不仅会干扰患者的生活质量，而且还具有剂量限制性，可能需要中断治疗。任何治疗肿瘤患者的肿瘤学家和皮肤科医生都必须非常了解这些皮肤并发症及其处理方法。
缩写
EGFR = 表皮生长因子受体，EGFRI = 表皮生长因子受体抑制剂
相似文献
1
Cutaneous complications of molecular targeted therapy used in oncology.肿瘤学中分子靶向治疗的皮肤并发症
J Med Life. 2016 Jan-Mar;9(1):19-25.
2
[Interdisciplinary management of cutaneous adverse events of EGFR inhibitors and multityrosine kinase inhibitors in oncology].
Dtsch Med Wochenschr. 2011 Jan;136(1-2):39-44. doi: 10.1055/s-0030-1269440. Epub 2010 Dec 21.
3
Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.靶向治疗的皮肤不良反应：第一部分：细胞膜抑制剂。
J Am Acad Dermatol. 2015 Feb;72(2):203-18; quiz 219-20. doi: 10.1016/j.jaad.2014.07.032.
4
Cutaneous adverse reactions specific to epidermal growth factor receptor inhibitors.表皮生长因子受体抑制剂特有的皮肤不良反应。
J Med Life. 2015;8 Spec Issue(Spec Issue):57-61.
5
[Skin toxicities and unmet supportive care needs of patients with cancer undergoing EGFR-inhibitor therapy].[接受表皮生长因子受体抑制剂治疗的癌症患者的皮肤毒性及未满足的支持性护理需求]
Pflege. 2017 Jan;30(1):9-17. doi: 10.1024/1012-5302/a000521. Epub 2016 Nov 30.
6
Cutaneous manifestations of nontargeted and targeted chemotherapies.非靶向和靶向化疗的皮肤表现。
Semin Oncol. 2016 Jun;43(3):419-25. doi: 10.1053/j.seminoncol.2016.02.018. Epub 2016 Feb 23.
7
[Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology].[肿瘤皮肤病学中使用的新型靶向抗癌疗法的皮肤不良事件]
Ann Chir Plast Esthet. 2012 Apr;57(2):106-13. doi: 10.1016/j.anplas.2012.02.002. Epub 2012 Mar 15.
8
[Cutaneous lesions due to inhibition of epidermal growth factor receptor].
Pathologe. 2006 Feb;27(1):53-6. doi: 10.1007/s00292-005-0803-0.
9
Skin Manifestations of Targeted Antineoplastic Therapy.靶向抗肿瘤治疗的皮肤表现
Curr Probl Dermatol. 2018;53:93-104. doi: 10.1159/000479198. Epub 2017 Nov 7.
10
[Cutaneous side effects of EGF-receptor inhibition and their management].[表皮生长因子受体抑制的皮肤副作用及其处理]
Hautarzt. 2006 Jun;57(6):509-13. doi: 10.1007/s00105-005-1033-3.
引用本文的文献
1
Neutrophilic eccrine hidradenitis following dasatinib initiation in a patient with chronic myeloid leukemia.一名慢性髓性白血病患者在开始使用达沙替尼后发生嗜中性小汗腺炎。
JAAD Case Rep. 2025 May 8;61:18-20. doi: 10.1016/j.jdcr.2025.03.033. eCollection 2025 Jul.
2
Erythema nodosum following treatment with dasatinib plus chemotherapy in a patient with myeloid blast phase of chronic myeloid leukemia.一名慢性髓性白血病髓系原始细胞期患者在接受达沙替尼加化疗治疗后出现结节性红斑。
Clin Case Rep. 2023 Nov 22;11(11):e8223. doi: 10.1002/ccr3.8223. eCollection 2023 Nov.
3
Systemic Steroid Treatment for Imatinib-Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study.系统激素治疗伊马替尼相关严重皮肤不良反应在胃肠道间质瘤患者中的应用：一项 II 期研究。
Oncologist. 2020 Nov;25(11):e1785-e1793. doi: 10.1634/theoncologist.2019-0953. Epub 2020 Jul 12.
4
Acute Paronychia and Reactive Capillary Proliferation in a Patient on Erlotinib.一名服用厄洛替尼的患者出现急性甲沟炎和反应性毛细血管增生
Indian J Dermatol. 2020 May-Jun;65(3):236-237. doi: 10.4103/ijd.IJD_348_18.
5
Antitumor pharmacotherapy of colorectal cancer in kidney transplant recipients.肾移植受者结直肠癌的抗肿瘤药物治疗
Ther Adv Med Oncol. 2019 Sep 23;11:1758835919876196. doi: 10.1177/1758835919876196. eCollection 2019.
6
Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond.甲状腺癌的靶向治疗：激酶抑制剂及其他。
Endocr Rev. 2019 Dec 1;40(6):1573-1604. doi: 10.1210/er.2019-00007.
7
Cutaneous Toxicities of Molecular Targeted Therapies.分子靶向治疗的皮肤毒性
Maedica (Bucur). 2017 Jan;12(1):48-54.
本文引用的文献
1
Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.免疫检查点抑制剂相关皮肌炎：细胞毒性 T 淋巴细胞相关抗原 4 阻断相关的新型免疫介导不良事件。
JAMA Dermatol. 2015 Feb;151(2):195-9. doi: 10.1001/jamadermatol.2014.2233.
2
Pyogenic granuloma as a cutaneous adverse effect of vemurafenib.化脓性肉芽肿作为维莫非尼的一种皮肤不良反应。
N Engl J Med. 2014 Sep 25;371(13):1265-7. doi: 10.1056/NEJMc1407683.
3
Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy.癌症化疗药物和靶向治疗的皮肤反应：第二部分。靶向治疗。
J Am Acad Dermatol. 2014 Aug;71(2):217.e1-217.e11; quiz 227-8. doi: 10.1016/j.jaad.2014.04.013.
4
Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs.癌症的化疗药物和靶向治疗的皮肤反应：第一部分。常规化疗药物。
J Am Acad Dermatol. 2014 Aug;71(2):203.e1-203.e12; quiz 215-6. doi: 10.1016/j.jaad.2014.04.014.
5
Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management.化疗引起的手足综合征和甲改变：临床特征、病因、发病机制和治疗的综述。
J Am Acad Dermatol. 2014 Oct;71(4):787-94. doi: 10.1016/j.jaad.2014.03.019. Epub 2014 May 1.
6
Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.用于癌症治疗的单克隆抗体的不良事件：聚焦超敏反应。
Oncoimmunology. 2013 Oct 1;2(10):e26333. doi: 10.4161/onci.26333. Epub 2013 Oct 17.
7
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.帕纳替尼治疗费城染色体阳性白血病的 2 期临床试验。
N Engl J Med. 2013 Nov 7;369(19):1783-96. doi: 10.1056/NEJMoa1306494. Epub 2013 Nov 1.
8
Vemurafenib and radiosensitization.威罗非尼与放射增敏。
JAMA Dermatol. 2013 Jul;149(7):855-7. doi: 10.1001/jamadermatol.2013.4200.
9
Eruptive melanocytic nevi in a patient undergoing treatment with sunitinib.一名正在接受舒尼替尼治疗的患者出现了发疹性黑素细胞痣。
JAMA Dermatol. 2013 May;149(5):624-6. doi: 10.1001/jamadermatol.2013.263.
10
Pseudoporphyria induced by imatinib mesylate.甲磺酸伊马替尼诱导的假性卟啉症。
Int J Dermatol. 2014 Feb;53(2):e143-4. doi: 10.1111/j.1365-4632.2012.05574.x. Epub 2013 Mar 3.
Zotero 插件